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ABSTRACT   
Fibroblast growth factors, FGF-1, FGF-2 and vascular endothelial growth factor (VEGF) are 
elevated in chronic inflamed airways. Airway smooth muscle (ASM) cells are known to 
synthesize VEGF. We investigated the contribution of FGF-1/-2 on the VEGF production in 
ASM cells, the involvement of mitogen-activated protein kinases (MAPK) and the 
modulatory effects of azithromycin and dexamethasone.  
Human ASM cells were treated with 10ng/ml FGF-1 or FGF-2. Specific blockers for 
ERK1/2
MAPK
 (U0126), p38
MAPK
 (SB239063), JNK (curcumin), dexamethasone or 
azithromycin were added 30 minutes prior to stimulation. Expression of VEGF (VEGF-A, 
VEGF121 and VEGF165) was assessed by quantitative PCR, VEGF release by ELISA and 
MAPK phosphorylation by Western blotting.  
FGF-1/-2 upregulated mRNA expression of VEGF (VEGF-A, VEGF121 and VEGF165) and its 
release by 1.8 fold (FGF-1) and 5.5 fold (FGF-2). Transient increase in ERK1/2
MAPK
 and 
p38
MAPK
 phosphorylation and subsequent release of VEGF from FGF-1/-2 treated human 
ASM cells was inhibited by respective blockers. Furthermore, both dexamethasone and 
azithromycin reduced the VEGF secretion mediated by the p38
MAPK
 pathway.  
In conclusion, we demonstrate that FGF-1 and FGF-2 upregulate VEGF production via 
ERK1/2
MAPK
 and p38
MAPK
 pathways. The anti-angiogeneic effect of dexamethasone and 
azithromycin may potentially contribute to tackle VEGF-mediated vascular remodelling in 
chronic airway diseases. 
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INTRODUCTION  
Chronic airway diseases such as asthma and COPD are characterized by expiratory airflow 
limitation due to thickening of the airway wall, repeated epithelial injury and a mixture of 
inflammatory exudates with excessive mucus secretion (1). Thickening of the airway wall is 
mostly caused by airway smooth muscle (ASM) cells hypertrophy and hyperplasia and 
subepithelial fibrosis (2), highlighting a pivotal role of ASM cells as effector cells during 
chronic airway inflammation (3;4). ASM cells are capable to synthesize and release a variety 
of extracellular matrix proteins that may perpetuate the inflammation and airway remodelling  
in atopic asthma and COPD (5;6). During chronic airway inflammation, fibroblast growth 
factor (FGF-2), a potent fibroproliferative factor is increased in the broncho-alveolar lavage 
(BAL) fluid of asthmatics (7). Furthermore, Kranenburg et al  showed a positive correlation 
of FGF-1, FGF-2 and FGF receptor-1 (FGFR-1) expression in the bronchial epithelium and 
ASM cells with the severity of COPD indicating that the FGF-FGFR system contributes to the 
pathogenesis of chronic airway diseases (8). 
Angiogenesis and deregulated bronchial vasculature are prominent in the structurally altered 
and inflamed airways which further contribute to the severity of chronic airway diseases (9). 
Vascular endothelial growth factor (VEGF), a homodimeric glycoprotein and endothelial cell 
specific mitogen, plays a key role in physiological and pathophysiological angiogenesis. 
There are at least five VEGF gene products termed as A to E of which VEGF-A (here after 
mentioned as VEGF) is a key regulator of angiogenesis and vascular permeability (10). 
Different isoforms of VEGF (VEGF121, 165, 189, 206) due to alternate splicing of its mRNA have 
been reported  (10). Increased VEGF levels are observed in BAL fluid, sputum and bronchial 
biopsies of asthma and COPD patients (9;11-13). Human ASM cells constitutively express 
VEGF and its isoforms of which VEGF121 is the dominant one (14).   
 
Willems-Widyastuti et al.                                                                          FGF induced VEGF 
5 
 
Airway structural changes are associated with bronchial angiogenesis and vascular 
remodelling of which the molecular mechanisms are not fully understood. We and others have 
shown that ASM cells express and release several growth factors in vitro in response to a 
number of stimuli (14;15). In view of the increased bronchial levels of FGFs and VEGF in 
patients with chronic airway diseases, we hypothesize that the FGF-FGFR-1 system 
contributes to angiogenesis and vascular remodelling via VEGF. An in vitro study was 
established using primary cultures of human ASM cells treated with FGF-1 or FGF-2 and 
assessing the VEGF production both at mRNA and protein level. Furthermore, we 
investigated the involvement of the mitogen-activated protein kinase (MAPK) pathway in the 
production of VEGF in FGF treated ASM cells.  
Currently, the combination of inhaled corticosteroid and long-acting β-adrenergic agonists is 
the main treatment modality for chronic airway diseases (16). Unfortunately, this treatment is 
less effective in severe asthmatic and smoking related diseases such as COPD (16;17). 
Treatment with macrolides is moving into the clinical practice of chronic lung disorders (18), 
and many studies already addressed their anti-inflammatory effect (19). Therefore, we 
explored the effects of the corticosteroid dexamethasone and the macrolide azithromycin on 
the release of VEGF by human ASM cells treated with FGFs and assessed its underlying 
signaling mechanisms in vitro. 
 
MATERIALS AND METHODS 
This study has been approved by the local medical ethical committee of the KUL (S51577) 
and the biosafety committee MS20101570 
Isolation and culture of human ASM cells  
Primary human ASM cells were isolated from trachea obtained from different donors (n=3 to 
6) for lung transplantation. Dissected smooth muscles were cut into small pieces and cultured 
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in DMEM supplemented with 10% fetal bovine serum (FBS), L-glutamine (2 mM), penicillin 
(100 U/ml), streptomycin (100 µg/ml) and amphotericin B (1,25 µg/ml) (Invitrogen, 
Merelbeke, Belgium), further maintained at 37°C in a humidified atmosphere of 5% CO2 as 
previously described (15). At confluence, ASM cells were verified for a spindle shaped 
morphology and “hill and valley pattern” by light microscopy and further characterized by 
immunocytochemistry for α-smooth muscle actin, smooth muscle myosin heavy chain (SM1 
and SM2) and calponin (Sigma-Aldrich, Bornem, Belgium). Confluent cells in the fourth to 
sixth passage were used for all experiments.  
 
Incubation of human ASM cells with FGFs 
ASM cells were seeded in 12 well plates or in T25 cm
2
 culture flasks and grown for 48 hours 
in DMEM before further grown in serum-deprived medium (DMEM containing 0.2% FBS) 
for 72 hours. Growth-arrested ASM cells were treated with 10ng/ml of FGF-1 or FGF-2 
(Sigma-Aldrich) in fresh serum-deprived medium. To verify the involvement of MAPK 
signaling pathway in VEGF release by ASM cells, the MAPK specific inhibitors  for ERK 
1/2
MAPK
: U0126 (10 µM), p38
MAPK
: SB239063 (10 µM) or JNK: curcumin (1 µM)(VWR; 
Haasrode, Belgium)were added 30 minutes prior to FGF treatment. To examine the possible 
role of dexamethasone (Sigma) and azithromycin (Sigma), ASM cells were pre-treated with 1 
µM dexamethasone or 10µM azithromycin 30 minutes prior to FGF incubation. Cell-
conditioned medium of each experiment was collected; cells were harvested in lyses buffer 
and stored at -80°C 
 
VEGF mRNA quantification by real-time PCR  
ASM cells were treated with 10ng/ml FGF-1 or FGF-2 for 1, 2, 4, 6 or 18 hours. Total cellular 
RNA was isolated using PureLink total RNA purification system (Invitrogen, Merelbeke, 
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Belgium). An on-column DNase digestion was incorporated into the procedure to remove any 
contaminating genomic DNA. Total RNA concentration was estimated by optical density 
measurements and an A260/A280 ratio of  1.8 was accepted. One µg of total RNA was used to 
generate cDNA using Ready-to-go T-primed First Strand Kit (GE Healthcare, Roosendaal, The 
Netherlands). Transcript levels were determined by real time PCR employing ABI prism 7700 
Sequence Detector System (Applied Biosystems, Foster City, CA) and using one step SYBR 
Green I PCR Master Mix Reagent Kit (Eurogentec, Herstal, Belgium). All oligonucleotide 
primers were purchased from Eurogentec (20). Each primer was used at a concentration of 0.3 
µM. The thermal cycler profile consisted of a 2-min step at 45°C, 10-min of Taq-polymerase 
activation at 95°C, followed by 40 cycles of PCR at 95°C for 15-sec and 60°C for 1-min. The 
results were quantified using comparative threshold (Ct) method. The Ct values of VEGF mRNA 
were normalized to Ct value of GAPDH mRNA, and presented as relative Ct value of VEGF 
mRNA expression. The relative Ct values of stimulated ASM cells to control (not-stimulated 
cells) were calculated using 2
-∆∆Ct
 formula as a fold change (21).  
 
VEGF protein measurement by ELISA 
Monolayer growth-arrested human ASM cells were incubated with 10ng/ml of FGF-1 or 
FGF-2 for 24 hours. The involvement of MAPK pathways in the secretion of VEGF was 
assessed by treating cells with U0126 (10 µM), SB239063 (10 µM) or curcumin (1 µM) for 
30 minutes prior to FGF stimulation. Similarly, the effect of dexamethasone (1 µM) or 
azithromycin (1 µM or 10 µM) on the release of VEGF were examined. VEGF protein 
concentrations were determined in 100 µl undiluted conditioned medium using a sandwich 
ELISA method according to the manufacturer’s instructions (R&D System Europe Ltd, 
Abingdon, UK). The concentration of VEGF was expressed in pg/ml, with a detection limit of 
5 pg/ml.  
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Quantification of MAPK activation by western blotting 
To determine the activation of MAPK pathway in response to FGF treatment, growth-arrested 
ASM cells were treated with 10 ng/ml of FGF-1 or FGF-2 for short periods (5, 10, 15, 30 or 
60 minutes). To examine the effects of specific inhibitors U0126, SB239063 or curcumin on 
MAPK activation, cells were treated with specific inhibitor 30 minutes prior to FGF 
stimulation. The effects of anti-inflammatory drugs were studied on cells pre-treated with 
dexamethasone (1 µM) or azithromycin (10 µM) for 30 minutes prior to FGF incubation for 
30 minutes.  Cells were washed twice with ice cold PBS before extraction of total protein 
using cell extraction buffer (Invitrogen) containing a cocktail of protease and phosphatase 
inhibitors (Complete/ PhosSTOP; Roche, Mannheim, Germany). The protein concentration 
was determined using a commercially available Bio-Rad protein assay kit (Bio-Rad; 
Nazareth, Belgium).  Protein extracts (50 µg) were fractionated by SDS-polyacrylamide 
gelelectrophoresis and transferred onto a PVDF membrane (GE Healthcare; Roosendaal, The 
Netherlands). The membranes were incubated for 1 hour with blocking agent (GE Healthcare) 
and consecutively overnight at 4°C with following primary antibodies: anti-total or anti-
phosphorylated p38
MAPK
, ERK 1/2
MAPK
 or JNK (Bioke; Leiden, the Netherland). After several 
washing steps, the target proteins were detected by the ECL western blotting detection system 
and ECL hyperfilm (GE Healthcare) according to the manufacturer’s instruction. Activation 
levels were expressed as the ratio of phosphorylated to non-phosphorylated signaling protein. 
 
Statistics 
The results were expressed as mean ± standard error of the mean (SEM) from 4-6 different 
experiments. Student’s t-test and Mann-Whitney U test was used for protein experiments 
(ELISA and Western Blotting) whereas one way ANOVA combined with Bonferroni test was 
employed for mRNA experiments (real-time PCR). Graphpad Prism 4.0 (San Diego, CA, 
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USA) was used for data analysis. Differences were considered statistically significant when 
p<0.05.   
 
RESULTS 
The effects of FGFs on the VEGF expression and secretion in human ASM cells 
Both FGF-1 and FGF-2 augmented VEGF mRNA expression in human ASM cells.  FGF-1 
induced the expression of VEGF-A, VEGF121 and VEGF165 in transient manner reaching 
maximal levels at 2h (n=5, p<0.001) and thereafter mRNA levels declined (figure 1A). 
However, FGF-2 induced VEGF mRNA expression as early as 2h, and this remained elevated 
up to 6h (n=5, p<0.001) and then the levels declined (figure 1B).  
In analogy to the mRNA expression, FGF-1 as well as FGF-2 significantly induced VEGF 
protein release after 24 h of stimulation (figure 1C). FGF-1 induced a 1.84 ±0.05 fold increase 
of VEGF production by ASM cells (n=5, p=0.0079) as compared to control whereas, FGF-2 
increased the VEGF protein secretion by 5.49±0.52 fold (n=5, p=0.0079) after 24 h of 
stimulation (Figure 1C). 
 
The activation of the MAPK pathways by FGFs  
Data shown in figure 2 demonstrated a rapid and robust phosphorylation of all three MAP 
kinases namely, ERK1/2
MAPK
, p38
MAPK
 and JNK 5 min before the levels declined gradually. 
Though levels declined, both FGF-1 and FGF-2 induced phosphorylation of ERK1/2
MAPK
 
remained significantly elevated even after 60 min of incubation as compared to respective 
controls. 
The effects of MAPK inhibitors and azithromycin on MAPK activation  
U0126 significantly reduced the rapid phosphorylation of ERK1/2
MAPK 
in response to FGF-1 
(Figure 3A, p=0.0088) as well as by FGF-2 (Figure 3B, p=0.0032). Similarly, when cells were 
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pretreated with SB239063, a significantly reduced p38
MAPK
 activation was observed in FGF-1 
(Figure 3C, p=0.0254) and FGF-2 (Figure 3D) treated human ASM cells. Pre-treatment with 
curcumin did not reduce FGFs induced JNK phosphorylation, despite rapid activation of this 
pathway in response to both FGF-1 and FGF-2 treatment (Figure 3E and 3F, respectively).  
 
The effect of azithromycin and dexamethasone on the MAPK pathway  
Pre-treatment with azithromycin or dexamethasone revealed no reduction in FGFs stimulated 
ERK1/2
MAPK
 phosphorylation. When cells were pretreated with azithromycin, a significant 
reduction in p38
MAPK
 activation was observed in both FGF-1 (Figure 3C, p=0.0236) as well as 
FGF-2 (Figure 3D, p=0.0323) stimulated human ASM cells. Dexamethasone pretreatment 
resulted in drastic inhibition of p38
MAPK
 activation in FGF-1 (p=0.0494) or FGF-2 (p=0.0261) 
stimulated cells whereas, ERK1/2
MAPK
 and JNK pathway remained unaffected. Interestingly, 
azithromycin also reduced JNK activation in response to FGF-2 treatment in ASM cells 
(Figure 3F, p=0.0244). 
 
The effects of MAPK inhibitors on the VEGF release 
A 24h of incubation with SB239063 resulted in significantly reduced levels of VEGF in 
conditioned media derived from FGF-1 (Figure 4A, p=0.0177) or FGF-2 (Figure 4B, 
p=0.0225) treated human ASM cells. Co-incubation of U0126 caused a significant attenuation 
of VEGF protein release either in FGF-1 (Figure 4A, p=0.0257) or in FGF-2 (Figure 4B,  
p=0.0051) stimulated human ASM cells. Curcumin could not reduce the VEGF protein 
release by FGF-1 or FGF-2-stimulated ASM cells (n=4, p=0.4176 and n=6, p=0.4075 
respectively).  
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The effect of azithromycin or dexamethasone on the VEGF release  
A reduction in VEGF protein release by 10 µM azithromycin was detected in FGF-1 (Figure 
5A, p=0.0081) as well as FGF-2 (Figure 5B, p=0.0011) treated cells after 24h. 
Dexamethasone (1 µM) treatment drastically decreased the VEGF protein release by FGF-1 
or FGF-2 stimulated human ASM cells (Figure 5A, p=0.0113 and Figure 5B, p<0.0001 
respectively). ASM cells were also treated for 24 h only with dexamethasone or azithromycin 
and the toxicity tests revealed that both drugs were not toxic to the cells (data not shown). 
 
DISCUSSION 
In this study, we demonstrated that FGF-1 and FGF-2 stimulation of ASM cells in vitro leads 
to: (i) increased expression of VEGF mRNA and its splice variants (VEGF121 and VEGF165) 
in a time dependent manner; (ii)  increased release of VEGF protein and that FGF-2 is more 
potent than FGF-1; (iii) activation of MAPK signaling pathways (ERK1/2
MAPK
 and p38
MAPK
) 
which mediate VEGF expression and release; (iv) p38
MAPK 
signaling pathway
 
mediated VEGF 
protein release from human ASM cells that is blocked by the anti-inflammatory drugs 
azithromycin and dexamethasone. 
FGF-1 and FGF-2 are prototypes of the FGF family whereas an increase in their expression 
has been reported in several pathophysiological conditions (7;8;22). Shute et al localized the 
bronchial FGF-heparan sulphate (FGF-HS) complex on endothelial and in bronchial epithelial 
basement membrane of asthmatic airways (22). Due to lack of secreting peptide, the release of 
biologically active FGF can occur by proteolytic degradation, during inflammatory processes 
or tissue damage (22). In this study, we attempted to mimic the pathophysiological condition 
of the increased FGF-1 and FGF-2 in chronic inflamed airways by investigating the role of 
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FGFs in modulating the production of angiogenic molecule, VEGF in human ASM cells in 
vitro.  
Having demonstrated that FGF-1/-2 induced VEGF production both at transcriptional as well 
as at translational level, our data showed the possible contribution of FGF-1 and FGF-2 in 
angiogenesis and vascular remodeling, a hallmark in chronic lung diseases (9;10). The 
involvement of VEGF in the pathogenesis of asthma is well documented (9;11;23). In the case 
of COPD, the expression of VEGF is associated with the development of the disease (9). 
Kanazawa et al reported that differences in VEGF expressions were significantly involved in 
the patho-physiology of the two major phenotypes of COPD, namely emphysema and chronic 
bronchitis (24). Chronic bronchitis was suspected to be the overlapping phase between the 
chronic inflammatory condition of asthma and an early stage of COPD (25). 
Santos et al reported the enhanced expression of VEGF in the pulmonary arteries of smokers 
and patients with moderate COPD (26), reflecting the possible effect of cigarette smoke on 
the increase of VEGF. The study of Rovina et al has confirmed that cigarette smoke 
significantly increases the VEGF level in the airways of both asymptomatic and bronchitis 
type COPD smokers (13). In a detailed study, Kranenburg and colleagues measured the 
cellular expression pattern of VEGF and its receptors, Flt-1 and KDR/Flk-1 in central and 
peripheral airways obtained from (ex)smokers, with or without COPD, and they showed that 
COPD is associated with increased expression of VEGF in bronchial, bronchiolar and alveolar 
epithelium, in bronchiolar macrophages, and also in airway and vascular smooth muscle (27).  
It is conceivable that cigarette smoke may, at least partly, be responsible for the increase in 
bronchial FGF-1 and FGF-2 expressions by provoking repeated episodes of injury and 
inflammatory processes leading to tissue remodeling in current/ex-smokers with COPD (8). In 
this study, we used human ASM cells derived from (healthy) donors. Our data showed that 
FGF-1 and FGF-2 are at least in part responsible for increased levels of VEGF in chronic 
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inflamed airways. Therefore, our results support a pathophysiological evidence for the 
involvement of VEGF in the development of COPD.  
The MAPK pathways, a family of serine-threonine proteins, are known to be involved in 
ASM cell proliferation in response to a variety of growth factors including TGF-β and FGF 
(28).  We demonstrated that the incubation of human ASM cells with FGF-1 or FGF-2 leads 
to the rapid and transient activation of MAPK pathways (ERK1/2
MAPK
, p38
MAPK
 and JNK). 
Furthermore, we found that ERK1/2
MAPK
 and p38
MAPK
 but not JNK signaling pathway 
mediates the production of VEGF after FGF-1/-2 treatment of human ASM cells.  
Keeping in mind the role of angiogenesis in chronic airway inflammation, we examined 
whether anti-inflammatory drugs such as dexamethasone and azithromycin may interrupt the 
release of VEGF protein from FGF-1/-2 stimulated ASM cells and whether MAPK signaling 
pathways were also involved in this process. Our data showed that dexamethasone and 
azithromycin individually decrease VEGF release from human ASM cells in response to 
FGF-1/-2 treatments. Their inhibitory effects were found to be mediated by p38
MAPK
 in 
particular. Our findings are in agreement with the work reported by Clark et al (29) on the 
p38
MAPK
 pathway deactivation by dexamethasone. In our study, dexamethasone, effectively 
inhibited both the p38
MAPK
 activation and the secretion of VEGF from human ASM cells in 
vitro.  
In addition to their antimicrobial activity, the immunomodulatory effect of macrolides like  
azithromycin to treat chronic airway diseases gained lots of interest in recent years (19), 
although the underlying mechanisms of its immunomodulation are still not clear.  
Interestingly, we also observed that, in response to FGF-2 (but not FGF-1), reduction of the 
VEGF release from ASM cells correlated with inhibition of JNK signaling pathway. These 
findings suggest for a potential effect of azithromycin as an anti-angiogenic and 
immunomodulatory agent at least driven by ASM cells. Due to its known side-effects, long-
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term treatment with corticosteroids is not advised. Since azithromycin shares the same 
signaling pathway as dexamethasone in exerting its inhibitory effect on the VEGF release, the 
combined treatment of both could allow a lower dosage of corticosteroids and hence decrease 
its side-effects. On the other hand, azithromycin or macrolides in general could enhance 
antimicrobial resistance (19).  Therefore, more studies are needed to investigate the safe and 
effective ways of applying this potential drug. 
Taken together, our findings suggest that FGF-1 and FGF-2, in addition to their role as 
extracellular matrix regulators, also function as pro-angiogenic growth factors that could play 
an important role in bronchial vascular remodeling via VEGF-mediated pathways. The anti-
inflammatory drugs, dexamethasone and azithromycin exert inhibitory effects on VEGF 
release in FGF-treated human ASM cells in vitro, thereby, introducing a clinical beneficial 
contribution of azithromycin and dexamethasone or in combination, to anti-angiogenic events 
in chronic inflammatory airway diseases.  
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LEGENDS: 
Fig.1A and B: VEGF mRNA expression and its splice variants VEGF121 and VEGF165 by 
human ASM cells that were either untreated (0h as basal level) and treated with 10 ng/ml 
of FGF-1 or FGF-2. Results are means±SEM of duplicate measurements representative 
from 5 human ASM donors and are normalized to GAPDH expressions. Results are 
expressed relative to VEGF expression in control cells compared with the basal 
level.*p<0.05; **p<0.01 and ***p<0.001. Fig.1C: FGF-1 or FGF-2 significantly increased 
VEGF protein release by human ASM cells after 24 h. Compared to untreated cells 
(control), FGF-1 increased VEGF release by ASM cells (46,42±4,45 vs 85,42±9,75 pg/ml; 
n=5 p=0,0159), whereas FGF-2 induced more on the VEGF secretion (52,48±11,49 vs 
275.60±33.48 pg/ml; n=5 p=0.0079). 
   
Fig.2A-F In response to FGF-1 or FGF-2 treatment, the ERK1/2
MAPK
, p38
MAPK
 or JNK 
pathway in human ASM cells was activated as early as 5 minutes. Control represented the 
non-treated cells. Results are shown as diagram and blots. The bar diagram depict the 
activation considered to the ratio between the phosphorylated per total. Values are shown 
as mean±SEM of independent experiments from 3 human ASM donors. *p<0.05, 
**p<0.01 and ***p<0.001. 
 
Fig.3A-F: Activation of ERK1/2
MAPK
, p38
MAPK
 or JNK pathway in response to FGF-1 or 
FGF-2 treatment in the presence of U0126, SB239063, curcumin or anti-inflammatory 
drugs dexamethasone and azithromycin was examined by western blotting. Control 
represented the non-treated cells. Results are shown as diagram and blots. The bar diagram 
depict the activation considered to the ratio between the phosphorilated per total. Data 
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represents the mean ± SEM of independent experiments from 3 ASM donors. *p<0.05, 
**p<0.003 
 
Fig.4: Release of VEGF protein by 10 ng/ml of FGF-1 or FGF-2 –stimulated human ASM 
cells, either in the absence (control) or presence of MAPK inhibitors: 10 µM SB239063 
(p38
MAPK
), 10 µM U0126 (ERK1/2
MAPK
) and 1 µM curcumin (JNK). Data represents the 
mean±SEM of independent experiments from 4-6 ASM donors (FGF-1 and FGF-2 
respectively). Data are expressed as fold change of VEGF release compared to their 
respective controls. *p<0.05 and **p<0.01 
 
Fig.5: Human ASM cells were stimulated with 10 ng/ml of FGF-1 or FGF-2 for 24 hours, 
either in the absence or presence of azithromycin (1 µM; 10 µM) or dexamethasone (1 
µM). Results represent the mean±SEM of duplicate measurements representative from 3 
ASM cells donors. Data are expressed as fold change of VEGF release compared to 
respective controls. *p<0.05, **p<0.01 and ***p<0.001 
 
 
 
